Traders purchased shares of Pfizer, Inc. (NYSE:PFE) on weakness during trading on Tuesday. $163.21 million flowed into the stock on the tick-up and $80.49 million flowed out of the stock on the tick-down, for a money net flow of $82.72 million into the stock. Of all equities tracked, Pfizer had the 5th highest net in-flow for the day. Pfizer traded down ($0.22) for the day and closed at $33.10
Several research firms have weighed in on PFE. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Jefferies Group LLC restated a “neutral” rating and issued a $35.00 target price (up previously from $34.00) on shares of Pfizer in a research note on Thursday, April 13th. BMO Capital Markets restated a “hold” rating and issued a $33.00 target price on shares of Pfizer in a research note on Thursday, April 27th. Sanford C. Bernstein restated a “buy” rating and issued a $35.00 target price on shares of Pfizer in a research note on Monday, April 24th. Finally, Credit Suisse Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $38.00 to $36.00 in a research note on Thursday, July 20th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $37.77.
The company’s 50-day moving average price is $33.38 and its 200 day moving average price is $33.25. The stock has a market capitalization of $200.76 billion, a price-to-earnings ratio of 24.61 and a beta of 1.00.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $0.64 earnings per share. Equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.80%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Pfizer during the fourth quarter worth $1,896,890,000. Fisher Asset Management LLC boosted its stake in shares of Pfizer by 3.9% in the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after buying an additional 1,275,832 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Pfizer by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock worth $1,117,696,000 after buying an additional 2,013,835 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Pfizer by 0.9% in the second quarter. Legal & General Group Plc now owns 31,463,283 shares of the biopharmaceutical company’s stock worth $1,056,857,000 after buying an additional 292,839 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after buying an additional 228,405 shares during the last quarter. Institutional investors and hedge funds own 69.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Investors Buy Shares of Pfizer, Inc. (PFE) on Weakness” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/06/investors-buy-shares-of-pfizer-inc-pfe-on-weakness-updated.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
